LBTD — Lotus Bio-Technology Development Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lotus Bio-Technology Development Corp., formerly Starflick.Com, is a biotechnology development company. The Company focuses on specializing in the refining of organic materials and the production of natural consumer related products. It is exploring opportunities in the organic growth and farming sector in China. The Company's operations are organizational matters, planning its Websites and developing its business plan. The Company is in start-up stage and has not generated any revenues.
Directors
- Last Annual
- March 31st, 2017
- Last Interim
- December 31st, 2017
- Incorporated
- March 24th, 2011
- Public Since
- March 14th, 2013
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 806,283,694
- Address
- Unit 04, 16/F, Tower 2 Silvercord, Kowloon, 00000
- Web
- Phone
- +852 63980212
- Auditors
- Malone Bailey, LLP
Similar to LBTD
1PM Industries
Pink Sheets on Nasdaq
3Dshopping.Com
Pink Sheets on Nasdaq
3 Sixty Risk Solutions
Pink Sheets on Nasdaq
Adecco AG
Pink Sheets on Nasdaq
Adm Endeavors
Pink Sheets on Nasdaq
FAQ
As of Today at 21:49 UTC, shares in Lotus Bio-Technology Development are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Lotus Bio-Technology Development last closed at $0.00 and the price had moved by -99.99% over the past 365 days. In terms of relative price strength the Lotus Bio-Technology Development share price has underperformed the S&P500 Index by -99.99% over the past year.
There is no consensus recommendation for this security.
Find out moreLotus Bio-Technology Development does not currently pay a dividend.
Lotus Bio-Technology Development does not currently pay a dividend.
Lotus Bio-Technology Development does not currently pay a dividend.
To buy shares in Lotus Bio-Technology Development you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Lotus Bio-Technology Development had a market capitalisation of .
Here are the trading details for Lotus Bio-Technology Development:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: LBTD
Based on an overall assessment of its quality, value and momentum Lotus Bio-Technology Development is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lotus Bio-Technology Development. Over the past six months, its share price has underperformed the S&P500 Index by -99.99%.
As of the last closing price of $0.00, shares in Lotus Bio-Technology Development were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lotus Bio-Technology Development PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lotus Bio-Technology Development's management team is headed by:
- Zoltan Nagy - PRE